[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556263":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":11,"centralContacts":38,"locations":44,"responsibleParty":61,"collaborators":11,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":11,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":11,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":11,"overallStatus":47,"whyStopped":11,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","INDUSTRY",[8,16,19,22],{"label":9,"type":10,"description":11,"interventionNames":12},"SSGJ-707(dose 1)+ carboplatin + paclitaxel","EXPERIMENTAL",null,[13,14,15],"Drug: SSGJ-707","Drug: carboplatin","Drug: paclitaxel",{"label":17,"type":10,"description":11,"interventionNames":18},"SSGJ-707(dose 2)+ carboplatin + paclitaxel",[13,14,15],{"label":20,"type":10,"description":11,"interventionNames":21},"SSGJ-707(dose 3)+ carboplatin + paclitaxel",[13,14,15],{"label":23,"type":10,"description":11,"interventionNames":24},"SSGJ-707(dose 4)+ paclitaxel",[13,15],[26,31,35],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"DRUG","SSGJ-707","SSGJ-707 is a bispecific antibody against human PD-1 and VEGF",[9,17,20,23],{"type":27,"name":32,"description":33,"armGroupLabels":34,"otherNames":11},"carboplatin","chemotherapy",[9,17,20],{"type":27,"name":36,"description":33,"armGroupLabels":37,"otherNames":11},"paclitaxel",[9,17,20,23],[39],{"name":40,"role":41,"phone":42,"phoneExt":11,"email":43},"ZHOU, PhD","CONTACT","13708384529","qizhou9128@163.com",[45],{"facility":46,"status":47,"city":48,"state":11,"zip":11,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Chongqing Cancer Hospital","RECRUITING","Chongqing","China","CN",{"type":52,"coordinates":53},"Point",[54,55],106.55771,29.56026,{"lat":55,"lon":54},[58],{"name":59,"role":41,"phone":60,"phoneExt":11,"email":43},"ZHOU QI, PhD","+86 13708384529",{"type":62,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100556263","phase-2-a-study-to-evaluate-ssgj-707-in-advanced-gynecologic-cancer-patients-100556263",false,"NCT06522828","A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients","A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 in Advanced Gynecologic Cancer Patients","Inclusion Criteria:\n\n1. Age:18-75 years old\n2. Advanced endometrial cancer and platinum-resistant ovarian cancer\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Expected survival \\>=12 weeks.\n5. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Known uncontrolled or symptomatic central nervous system metastatic disease.\n2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \\>1 (National Cancer Institute Common terminology Criteria \\[NCI CTCAE\\] v.5.0).\n3. Inadequate organ or bone marrow function.\n4. Pregnant or breast-feeding woman.\n5. Known allergies, hypersensitivity, or intolerance to SSGJ-707 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","ALL","18 Years","75 Years",{"count":74,"type":75},80,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced\u002Frecurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced\u002Frecurrent endometrial cancer and platinum-resistant ovarian cancer.",[81],"Advanced\u002Frecurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer","2024-10-17",{"date":84,"type":85},"2024-10-21","ACTUAL",{"date":87,"type":85},"2024-10-10",{"date":89,"type":75},"2026-08",{"name":5,"class":6},1]